Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Trends Biotechnol. 2013 Jul;31(7):390-6. doi: 10.1016/j.tibtech.2013.04.007. Epub 2013 May 31.
Nuclear medicine has been contributing towards personalized therapies. Nuclear reactors are required for the working horses of both diagnosis and treatment, i.e., Tc-99m and I-131. In fact, reactors will remain necessary to fulfill the demand for a variety of radionuclides and are essential in the expanding field of targeted radionuclide therapies for cancer. However, the main reactors involved in the global supply are ageing and expected to shut down before 2025. Therefore, the fields of (nuclear) medicine, nuclear industry and politics share a global responsibility, faced with the task to secure future access to suitable nuclear reactors. At the same time, alternative production routes should be industrialized. For this, a coordinating entity should be put into place.
核医学一直在为个性化治疗做出贡献。核反应堆是诊断和治疗的“主力军”，即 Tc-99m 和 I-131 所必需的。实际上，反应堆仍然是满足各种放射性核素需求的必要条件，并且对于癌症的靶向放射性核素治疗领域的扩展也是必不可少的。但是，参与全球供应的主要反应堆正在老化，预计将在 2025 年前关闭。因此，（核）医学、核工业和政治领域共同承担着全球责任，面临着确保未来获得合适的核反应堆的任务。同时，应工业化替代生产途径。为此，应该建立一个协调实体。
